Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Merchant

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Cancer Research|June 4, 2008
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survivalHongkui Jin, Renhui Yang, Zhong Zheng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2012
Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictionsEdna F Choo, Marcia Belvin, Jason Boggs, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.
Molecular and Cellular Biology|August 2, 2005
Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalusMark Merchant, Marie Evangelista, Shiuh-Ming Luoh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Cancer Research|March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growthTed Lau, Emily Chan, Marinella Callow, et al.
Molecular Cancer Therapeutics|November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancerMelissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Cancer Research|June 4, 2008
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survivalHongkui Jin, Renhui Yang, Zhong Zheng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2012
Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictionsEdna F Choo, Marcia Belvin, Jason Boggs, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.
Molecular and Cellular Biology|August 2, 2005
Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalusMark Merchant, Marie Evangelista, Shiuh-Ming Luoh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung AdenocarcinomaAnneleen Daemen, Jonathan E Cooper, Szymon Myrta, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Cancer Research|March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growthTed Lau, Emily Chan, Marinella Callow, et al.
Molecular Cancer Therapeutics|November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancerMelissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Cancer Research|August 19, 2017
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate CancerLingyan Jin, Jesse Garcia, Emily Chan, et al.
Pageof 11